These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 6861851)
1. Effect of dosage frequency of carbamazepine on drug serum levels in epileptic patients. Ghose K; Fry DE; Christfides JA Eur J Clin Pharmacol; 1983; 24(3):375-81. PubMed ID: 6861851 [TBL] [Abstract][Full Text] [Related]
2. Once daily dosage versus divided daily doses of carbamazepine therapy in epileptic patients: a pilot study. Ghose K; Dawson M; Fry DE; Christofides JA Pharmatherapeutica; 1981; 3(1):71-8. PubMed ID: 7033994 [TBL] [Abstract][Full Text] [Related]
3. Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients. McKee PJ; Blacklaw J; Carswell A; Gillham RA; Brodie MJ Br J Clin Pharmacol; 1993 Sep; 36(3):257-61. PubMed ID: 9114913 [TBL] [Abstract][Full Text] [Related]
4. Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects. Bareggi SR; Tata MR; Guizzaro A; Pirola R; Parisi A; Monza CG Int Clin Psychopharmacol; 1994; 9(1):9-16. PubMed ID: 8195585 [TBL] [Abstract][Full Text] [Related]
5. [A practical study of the efficacy of a delayed-action preparation of carbamazepine (Tegretol CR 400) in the treatment of patients with partial epilepsy ]. Vojvodić NM; Sokić DV; Janković SM; Lević Z Srp Arh Celok Lek; 2002; 130(1-2):19-26. PubMed ID: 12073283 [TBL] [Abstract][Full Text] [Related]
6. Carbamazepine drug interactions: the influence of concurrent drug therapy on serum concentrations of carbamazepine and its epoxide metabolite. Wang RB; Liu LT; Yiu CH; Chang TY Zhonghua Yi Xue Za Zhi (Taipei); 1990 Apr; 45(4):222-32. PubMed ID: 2168269 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy. Garnett WR; Levy B; McLean AM; Zhang Y; Couch RA; Rudnic EM; Pellock JM; Belendiuk GW Epilepsia; 1998 Mar; 39(3):274-9. PubMed ID: 9578044 [TBL] [Abstract][Full Text] [Related]
8. Multiple-dose pharmacokinetic study with a slow-release carbamazepine preparation. Reunanen M; Heinonen E; Anttila M; Järvensivu P; Lehto H; Hokkanen E Epilepsy Res; 1990 Jul; 6(2):126-33. PubMed ID: 2387286 [TBL] [Abstract][Full Text] [Related]
9. Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients. McKee PJ; Blacklaw J; Butler E; Gillham RA; Brodie MJ Br J Clin Pharmacol; 1991 Jul; 32(1):99-104. PubMed ID: 1888646 [TBL] [Abstract][Full Text] [Related]
10. Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children. Hartley R; Forsythe WI; McLain B; Ng PC; Lucock MD Clin Pharmacokinet; 1991 Mar; 20(3):237-46. PubMed ID: 2025982 [TBL] [Abstract][Full Text] [Related]
11. Adjustment of carbamazepine dose to offset the effects of the interaction with remacemide hydrochloride in a double-blind, multicentre, add-on drug trial (CR2237) in refractory epilepsy. Mawer GE; Jamieson V; Lucas SB; Wild JM Epilepsia; 1999 Feb; 40(2):190-6. PubMed ID: 9952266 [TBL] [Abstract][Full Text] [Related]
12. Reduction of dosing frequency of carbamazepine with a slow-release preparation. Sivenius J; Heinonen E; Lehto H; Järvensivu P; Anttila M; Ylinen A; Riekkinen P Epilepsy Res; 1988; 2(1):32-6. PubMed ID: 3197677 [TBL] [Abstract][Full Text] [Related]
13. Carbamazepine and carbamazepine-10,11-epoxide serum concentrations in epileptic children. Furlanut M; Montanari G; Bonin P; Casara GL J Pediatr; 1985 Mar; 106(3):491-5. PubMed ID: 3973787 [TBL] [Abstract][Full Text] [Related]
14. Developmental and therapeutic pharmacology of antiepileptic drugs. Miura H Epilepsia; 2000; 41 Suppl 9():2-6. PubMed ID: 11156504 [TBL] [Abstract][Full Text] [Related]
15. Treatment of epilepsy in mentally retarded patients with a slow-release carbamazepine preparation. Kaski M; Heinonen E; Sivenius J; Tuominen J; Anttila M J Ment Defic Res; 1991 Jun; 35 ( Pt 3)():231-9. PubMed ID: 1920391 [TBL] [Abstract][Full Text] [Related]
16. Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects. Tomson T Arch Neurol; 1984 Aug; 41(8):830-4. PubMed ID: 6466158 [TBL] [Abstract][Full Text] [Related]
17. Effects of discontinuation of phenytoin, carbamazepine, and valproate on concomitant antiepileptic medication. Duncan JS; Patsalos PN; Shorvon SD Epilepsia; 1991; 32(1):101-15. PubMed ID: 1985818 [TBL] [Abstract][Full Text] [Related]
18. Clinical monitoring during carbamazepine slow-release, once-daily monotherapy. Stefan H; Schäfer H; Kuhnen C; Schneider S Epilepsia; 1988; 29(5):571-7. PubMed ID: 3137020 [TBL] [Abstract][Full Text] [Related]
19. Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients. Thakker KM; Mangat S; Garnett WR; Levy RH; Kochak GM Biopharm Drug Dispos; 1992 Nov; 13(8):559-69. PubMed ID: 1421050 [TBL] [Abstract][Full Text] [Related]